Artiva Biotherapeutics, Inc. ARTV Operating Lease Liability Payments - 2027 (Lessee)

Operating Lease Liability Payments - 2027 (Lessee) at other companies

Allogene TherapeuticsALLO

——

Immix Biopharma, Inc.IMMX

——

ImmunityBio, Inc.IBRX

——

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Operating margin-83.9%—

Net margin-79.3%—

Return on equity-67.9%—

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Artiva Biotherapeutics, Inc.'s operating lease liability payments - 2027 (lessee)?: Artiva Biotherapeutics, Inc. (ARTV) reported operating lease liability payments - 2027 (lessee) of $2.28M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s operating lease liability payments - 2027 (lessee) changed year-over-year?: Artiva Biotherapeutics, Inc.'s operating lease liability payments - 2027 (lessee) decreased by 39.1% year-over-year, from $3.75M to $2.28M.